NCT01782274: Proteome-based Immunotherapy of Brain Metastases From Breast Cancer

NCT01782274
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Enrolling by invitation
Ph+ase 2|Ph+ase 3
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT01782274

Comments are closed.

Up ↑